Aethyl-3,4-dimethoxy-oxanilat | 17894-50-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: Aethyl-3,4-dimethoxy-oxanilat
• 英文别名: ethyl 2-[(3,4-dimethoxyphenyl)amino]-2-oxoacetate；Ethyl [(3,4-dimethoxyphenyl)amino](oxo)acetate；ethyl 2-(3,4-dimethoxyanilino)-2-oxoacetate
• CAS: 17894-50-7
• 化学式: C₁₂H₁₅NO₅
• mdl: MFCD10018357
• 分子量: 253.255
• InChiKey: JXKNINRETCQHQQ-UHFFFAOYSA-N

物化性质

• 熔点：
  102-103 °C
• 密度：
  1.223±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  18
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  73.9
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  Aethyl-3,4-dimethoxy-oxanilat 在 potassium hydroxide 作用下， 以 四氢呋喃 、 水 为溶剂， 生成 (3,4-dimethoxy-phenyl)-oxalamic acid
  参考文献：
  名称：

  10.1002/adsc.202400356

  摘要：

  A visible‐light‐promoted strategy for the decarboxylative C‐3 carbamoylation of quinoxalinone scaffolds is developed. This approach initiates through the formation of an EDA complex between oxamic acid and quinoxalinone. Successive SET and decarboxylative carbamoylation construct the C‒C bond. This method utilizes aerial oxygen as the green oxidant and eradicates the process from the use of external photocatalysts and transition metals. Detailed synthetic and photophysical studies enlighten the reaction pathway.

  DOI：

  10.1002/adsc.202400356
• 作为产物：
  描述：

  草酰氯单乙酯 、 3,4-二甲氧基苯胺 以 乙醚 为溶剂， 反应 24.0h， 以98%的产率得到Aethyl-3,4-dimethoxy-oxanilat
  参考文献：
  名称：

  A New Approach to Methoxyisatins Leading to the Total Synthesis of Ophiuroidine and Other Hydroxytryptanthrins

  摘要：

  本文介绍了一种从相应的甲氧基苯胺制备甲氧基靛红的新方法。得到的甲氧基异砹被用于合成几种甲氧基色黄素化合物。利用微波介导的 Prey 去甲基化法，从相应的三甲氧基前体中获得了天然产物表黑啶（4,8,9-三羟基色黄素）。

  DOI：

  10.1055/s-0029-1217004

文献信息

• [EN] PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF<br/>[FR] INHIBITEURS DE L'ACTIVATEUR 1 DU PLASMINOGÈNE ET LEURS PROCÉDÉS D'UTILISATION
  申请人：UNIV MICHIGAN

  公开号：WO2014070983A1

  公开（公告）日：2014-05-08

  The invention relates to plasminogen activator- 1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

  本发明涉及纤溶酶原激活剂-1（PAI-1）抑制剂化合物及其在治疗与PAI-1水平升高相关的任何疾病或失调症中的用途。发明包括但不限于使用这些化合物来预防或减少血栓形成和纤维化，促进血栓溶解，以及调节脂质代谢和治疗与PAI-1、胆固醇或脂质水平升高相关的疾病或失调症。
• NON-BASIC MELANIN CONCENTRATING HORMONE RECEPTOR-1 ANTAGONISTS AND METHODS
  申请人：Stein Philip D.

  公开号：US20090011994A1

  公开（公告）日：2009-01-08

  The present application provides compounds, including all stereoisomers, solvates, prodrugs and pharmaceutically acceptable forms thereof according to Formula I wherein R 1 , R 2 , R 3 , R 8 , and R 9 are defined herein. Additionally, the present application provides pharmaceutical compositions containing at least one compound according to Formula I and optionally at least one additional therapeutic agent. Finally, the present application provides methods for treating a patient suffering from an MCHR-1 modulated disease or disorder such as, for example, obesity, diabetes, depression or anxiety by administration of a therapeutically effective dose of a compound according to Formula I.

  本申请提供了根据公式I提供的化合物，包括所有立体异构体、溶剂合物、前药和药学上可接受的形式， 其中 R 1 ，R 2 ，R 3 ，R 8 和R 9 在此定义。 此外，本申请提供了含有至少一种根据公式I的化合物和可选至少一种额外治疗剂的药物组合物。最后，本申请提供了治疗患有MCHR-1调节性疾病或紊乱的患者的方法，例如肥胖症、糖尿病、抑郁症或焦虑症，通过给予根据公式I的化��物的治疗有效剂量。
• PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：THE REGENTS OF THE UNIVERSITY OF MICHIGAN

  公开号：US20150315178A1

  公开（公告）日：2015-11-05

  The invention relates to plasminogen activator-1 (PAI-1) inhibitor compounds and uses thereof in the treatment of any disease or disorder associated with elevated PAI-1. The invention includes, but is not limited to, the use of such compounds to prevent or reduce thrombosis and fibrosis, to promote thrombolysis, and to modulate lipid metabolism and treat diseases or disorders associated with elevated PAI-1, cholesterol, or lipid levels.

  本发明涉及纤溶酶原激活剂-1（PAI-1）抑制剂化合物及其在治疗任何与高PAI-1相关的疾病或障碍中的应用。本发明包括但不限于使用这些化合物来预防或减少血栓形成和纤维化，促进溶栓，调节脂质代谢并治疗与高PAI-1，胆固醇或脂质水平相关的疾病或障碍。
• PLASMINOGEN ACTIVATOR-1 INHIBITORS AND METHODS OF USE THEREOF
  申请人：The Regents of The University of Michigan

  公开号：EP2914575B1

  公开（公告）日：2020-10-14
• US9718760B2
  申请人：——

  公开号：US9718760B2

  公开（公告）日：2017-08-01